Ginetta Collo

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8085312/ginetta-collo-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44 papers	3,848 citations	25 h-index	48 g-index
48 ext. papers	4,088 ext. citations	4.9 avg, IF	4.71 L-index

#	Paper	IF	Citations
44	Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
43	Pharmacology profile of F17464, a dopamine D receptor preferential antagonist. *European Journal of Pharmacology*, **2021**, 890, 173635	5.3	10
42	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. *Frontiers in Neuroscience*, **2020**, 14, 632	5.1	5
41	A human translational model based on neuroplasticity for pharmacological agents potentially effective in Treatment-Resistant Depression: focus on dopaminergic system. *Neural Regeneration Research*, **2020**, 15, 1027-1029	4.5	3
40	Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression. *Chronic Stress*, **2019**, 3, 2470547019842545	3	1
39	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. *Biochemical Pharmacology*, **2019**, 163, 154-168	6	10
38	Ketamine increases the expression of GluR1 and GluR2 □amino-3-hydroxy-5-methy-4-isoxazole propionate receptor subunits in human dopaminergic neurons differentiated from induced pluripotent stem cells. *NeuroReport*, **2019**, 30, 207-212	1.7	10
37	Ketamine effects on mammalian target of rapamycin signaling in the mouse limbic system depend on functional dopamine D3 receptors. *NeuroReport*, **2018**, 29, 615-620	1.7	4
36	Alpha6-Containing Nicotinic Acetylcholine Receptors Mediate Nicotine-Induced Structural Plasticity in Mouse and Human iPSC-Derived Dopaminergic Neurons. *Frontiers in Pharmacology*, **2018**, 9, 572	5.6	3
35	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. *Neural Plasticity*, **2018**, 2018, 4196961	3.3	23
34	Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment. *European Journal of Human Genetics*, **2018**, 26, 1824-1831	5.3	7
33	Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression. *Neural Regeneration Research*, **2018**, 13, 645-646	4.5	10
32	Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. *Molecular Psychiatry*, **2018**, 23, 812-823	15.1	73
31	(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. *NeuroReport*, **2018**, 29, 1425-1430	1.7	20
30	Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neuron differentiation potential. *Scientific Reports*, **2017**, 7, 6036	4.9	17
29	The Integrin □64 in Epithelial and Carcinoma Cells **2017**, 177-196		
28	Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. *European Neuropsychopharmacology*, **2015**, 25, 1437-47	1.2	32

27	Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings. *Progress in Brain Research*, **2014**, 211, 255-75	2.9	40
26	Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine. *Frontiers in Pharmacology*, **2014**, 5, 259	5.6	39
25	Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. *Molecular Pharmacology*, **2013**, 83, 1176-89	4.3	49
24	Pre-synaptic dopamine D(3) receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. *Journal of Neurochemistry*, **2012**, 120, 765-78	6	36
23	Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. *PLoS ONE*, **2011**, 6, e27959	3.7	46
22	The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons. *Journal of Neurochemistry*, **2011**, 117, 253-63	6	23
21	The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. *Journal of Receptor and Signal Transduction Research*, **2010**, 30, 347-54	2.6	32
20	Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. *Journal of Neurochemistry*, **2008**, 106, 560-77	6	63
19	Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. *European Journal of Neuroscience*, **2008**, 28, 1231-40	3.5	40
18	Immature neuronal phenotype derived from mouse skin precursor cells differentiated in vitro. *Brain Research*, **2006**, 1109, 32-6	3.7	4
17	The NMDA/D1 receptor complex as a new target in drug development. *Current Topics in Medicinal Chemistry*, **2006**, 6, 801-8	3	65
16	Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. *Molecular Pharmacology*, **2006**, 69, 805-12	4.3	73
15	Differential onset of expression of alpha 7 and beta 1D integrins during mouse heart and skeletal muscle development. *Cell Adhesion and Communication*, **1998**, 5, 193-205		45
14	Blockade of Human P2X7 Receptor Function With a Monoclonal Antibody. *Blood*, **1998**, 92, 3521-3528	2.2	9
13	The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. *Journal of Biological Chemistry*, **1997**, 272, 5482-6	5.4	395
12	Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. *Journal of Cell Biology*, **1997**, 138, 697-706	7.3	152
11	ATP-mediated cytotoxicity in microglial cells. *Neuropharmacology*, **1997**, 36, 1295-301	5.5	257
10	Tissue distribution of the P2X7 receptor. *Neuropharmacology*, **1997**, 36, 1277-83	5.5	438

9	P2X1 receptor activation in HL60 cells. *Blood*, **1996**, 87, 2659-2664	2.2	78
8	An antagonist-insensitive P2X receptor expressed in epithelia and brain.. *EMBO Journal*, **1996**, 15, 55-62	13	324
7	Cloning OF P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. *Journal of Neuroscience*, **1996**, 16, 2495-507	6.6	811
6	Distinct alpha 7A beta 1 and alpha 7B beta 1 integrin expression patterns during mouse development: alpha 7A is restricted to skeletal muscle but alpha 7B is expressed in striated muscle, vasculature, and nervous system. *Developmental Dynamics*, **1996**, 207, 355-71	2.9	58
5	Purinoceptors in the central nervous system **1996**, 39, 361-370		6
4	P2X receptors: an emerging channel family. *European Journal of Neuroscience*, **1996**, 8, 2221-8	3.5	247
3	Gradient of integrin alpha 6A distribution in the myocardium during early heart development. *Cell Adhesion and Communication*, **1995**, 3, 101-13		27
2	Distinctive Functions of β4 and Other Integrins in Epithelial Cells **1994**, 141-161		2
1	Cell type-specific integrin variants with alternative alpha chain cytoplasmic domains. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 10183-7	11.5	180